Setback for Moderna in patent dispute with mRNA competitors

Moderna has suffered a setback in a patent battle against their worst competitors in covid vaccines, Biontech and its partner Pfizer.

The European Patent Office, EPO, declared last week that a patent in mRNA technology, owned by Moderna, is invalid. This is reported by Reuters.

Moderna has sued Biontech in Germany and other countries, claiming that the company has copied mRNA technology that Moderna had patented long before covid-19 appeared in 2019.

Moderna has announced that it intends to appeal the decision.

Artikeln är en del av vårt tema om News in English.

Kommentera en artikel
Utvalda artiklar


Sänd till en kollega